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Abstract: SLT-VEGF is a recombinant cytotoxin comprised of Shiga-like toxin (SLT) 
subunit A fused to human vascular endothelial growth factor (VEGF). It is highly cytotoxic 
to tumor endothelial cells overexpressing VEGF receptor-2 (VEGFR-2/KDR/Flk1) and 
inhibits the growth of primary tumors in subcutaneous models of breast and prostate cancer 
and inhibits metastatic dissemination in orthotopic models of pancreatic cancer. We 
examined the efficacy of SLT-VEGF in limiting tumor growth and metastasis in an 
orthotopic melanoma model, using NCR athymic nude mice inoculated with highly 
metastatic Line IV Cl 1 cultured human melanoma cells. Twice weekly injections of   
SLT-VEGF were started when tumors became palpable at one week after intradermal 
injection of 1 × 10
6 cells/mouse. Despite selective depletion of VEGFR-2 overexpressing 
endothelial cells from the tumor vasculature, SLT-VEGF treatment did not affect tumor 
growth. However, after primary tumors were removed, continued SLT-VEGF treatment led 
to fewer tumor recurrences (p  = 0.007), reduced the incidence of lung metastasis 
(p = 0.038), and improved survival (p = 0.002). These results suggest that SLT-VEGF is 
effective at the very early stages of tumor development, when selective killing of VEGFR-2 
overexpressing endothelial cells can still prevent further progression. We hypothesize that 
SLT-VEGF could be a promising adjuvant therapy to inhibit or prevent outgrowth of 
metastatic foci after excision of aggressive primary melanoma lesions. 
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1. Introduction 
The role of angiogenesis in supporting tumor growth and metastasis is well established [1]. Tumors 
have been shown to secrete pro-angiogenic molecules that induce vascular growth and allow tumor 
cells to gain access to nutrients as well as provide cellular escape routes. Vascular endothelial growth 
factor (VEGF) is a key stimulator of angiogenesis, whose receptors, particularly VEGFR-2, are 
overexpressed in endothelial cells in tumor vasculature. Once proangiogenic molecules, like VEGF, 
are no longer balanced out by endogenous anti-angiogenic molecules, an angiogenic “switch” occurs, 
which initiates the vascular phase of tumor growth [2]. Because of the prominence of VEGF/VEGFR 
signaling, the majority of approved and experimental anti-angiogenesis therapeutics target VEGF and 
VEGFR-2 [3,4]. Such targets seemed particularly attractive for long term treatment since, unlike 
cancer cells, endothelial cells comprising the tumor vasculature lack the genetic instability that allows 
drug resistance to develop [5]. 
The clinical experience with VEGF/VEGFR inhibitors has been discouraging since, although many 
types of tumors respond well to these inhibitors initially, they all rapidly develop resistance and 
patients almost invariably relapse within one year of starting treatment [6,7]. The resistance to 
anti-angiogenic drugs appears to be associated with mechanism(s) of their action. Although inhibitors 
of VEGF/VEGFR signaling were expected to inhibit tumor growth via inhibition of endothelial cell 
proliferation, experimental evidence and clinical observations indicate that it induces actual vascular 
regression, most likely by inhibiting pro-survival VEGF functions [8,9]. Vascular regression, in turn, 
leads to hypoxia in tumors and upregulation of VEGF production, which stimulates tumor 
revascularization after either prolonged exposure to the drugs or during interruptions in treatment [10]. 
Surprisingly, revascularization appears to involve endothelial cells that are resistant to VEGF/VEGFR 
inhibitors through mechanisms that are not fully understood. These may include reliance on alternative 
signaling pathways or development of resistance to the employed drugs [6]. 
An alternative approach to anti-angiogenic therapy is to subvert VEGFR for selective delivery of 
highly cytotoxic agents into endothelial cells, with the expectation that only tumor endothelial cells 
overexpressing such receptors will internalize therapeutically significant amounts of VEGFR-targeted 
cytotoxins. Since alternative signal transduction pathways cannot prevent or reverse the cytotoxic 
activity of plant or bacterial toxins, several groups have used VEGF for targeting such toxins to tumor 
vasculature [11]. One such protein is SLT-VEGF, which is comprised of human VEGF121 fused to 
SLT, a site-specific N-glycosidase from Shiga-like toxin [12]. Upon internalization, the SLT moiety 
cleaves off adenosine 4324 in 28S rRNA, which prevents the ribosome from properly interacting with 
elongation factors thus impeding protein synthesis and eventually leading to cell death. SLT-VEGF is 
highly cytotoxic to VEGFR-2 overexpressing cells in vitro, and selectively depletes such cells in tumor 
vasculature of autologous mouse 4T1 mammary carcinoma tumors and of human PC3 prostate tumor 
xenografts. It inhibits primary tumor growth in these models and also inhibits metastatic dissemination 
in two orthotopic pancreatic tumor models [11,13]. Toxins 2010, 2  
 
 
2244
Judging by the mechanism of SLT-VEGF action, its efficacy should depend on the contribution of 
VEGFR-2 overexpressing cells to the survival and growth of primary tumors and metastatic lesions at 
various stages of tumor development through the course of treatment. In this study, we explored the 
effects of SLT-VEGF on development of primary tumors, and on tumor recurrence and metastatic 
dissemination after primary tumor excision, using an orthotopic xenograft model of highly metastatic 
melanoma tumors derived from Line IV Cl 1 human melanoma cells [14,15]. We reasoned that such a 
model would be relevant to the clinical setting of human melanoma patients undergoing primary tumor 
excision who are at risk of local tumor recurrence and/or development of distant metastases. 
2. Materials and Methods 
2.1. Cultured Cells 
Line IV Cl 1 human melanoma cells were a gift from Dr. B.C. Giovanella (The Cancer Research 
Laboratory, St. Joseph Hospital, Houston, TX). Orthotopic tumors derived from these cells have a high 
metastatic potential in nude mice as previously shown by Heim et al. [14] and confirmed by 
Hamby et al. [15]. They were maintained in RPMI-1640 (Lonza, Walkersville, MD) with 10% bovine 
growth serum (BGS)(HyClone, Logan, Utah). Porcine aortic endothelial (PAE) cells were obtained 
from the American Type Tissue Collection (Rockville, MD) and PAE cells stably transfected with 
human KDR (PAE/KDR) were derived as described [16]. The latter cell lines were maintained in 
DMEM (Lonza, Walkersville, MD) with 10% BGS. All cell lines were incubated at 37 °C in a   
5% CO2 atmosphere. 
2.2. Research Reagents  
SLT-VEGF was constructed, expressed and purified as described previously [12] and supplied by 
SibTech, Inc. Purified human IFN-α was obtained from the NIAID Reference Reagent Repository 
administered by KamTek, Inc., in Gaithersburg, MD. The lyophilized powder was reconstituted in 
sterile injection saline and stored in aliquots in vapor phase liquid nitrogen. 
2.3. Growth Inhibition Assay 
Target cells were seeded in triplicate at 1 × 10
3 cells/well in 96 well plates (Falcon, Becton 
Dickinson, Franklin Lakes, NJ). The cells were allowed to attach for 24 hours before different 
concentrations of SLT-VEGF were added to the cultures. After 3 days incubation at 37 °C in 5% CO2, 
20 μL/well of CellTiter 96
® AQueous One Solution Reagent (Promega, Madison, WI) was added to 
plates and allowed to incubate for 1 hour. The color change was read at 490 nm on a 96 well plate 
reader (Bio-Rad, Hercules CA, USA). The percent growth inhibition at each concentration of 
SLT-VEGF was calculated by comparison to untreated control wells. 
2.4. Caspase Assays 
PAE/KDR cells and Line IV Cl 1 human melanoma cells were plated in 8 well chamber slides 
(BD Falcon, Franklin Lakes, NJ) at 3 × 10
4 cells per chamber in 200 µL of DMEM with 10% BGS. 
The cells were allowed to attach overnight and treated the next day with 26 nM SLT-VEGF. At 18 and Toxins 2010, 2  
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22 hours after addition of SLT-VEGF, the media was removed and 100 µL of a 30× FLICA™ working 
solution from Vybrant
® FAM Caspase Kits (Molecular Probes, Carlsbad, CA) specific for caspase 8 or 
caspases 3 and 7 were added to slide chambers according to the manufacturer’s instructions. The 
fluoromethyl ketone moiety of these reagents covalently binds to cysteine residues of activated 
caspases in cells and can be visualized by the carboxyfluorescein (FAM) reporter. A 2.85 μg/mL 
solution of 4',6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich, St. Louis, MO) was added to stain 
cell nuclei. The chamber apparatus was then removed from the slide and coverslips were mounted with 
Vectashield medium (Vector Laboratories, Burlingame, CA). The slides were analyzed on a Zeiss 
Axiovert 200 microscope (Carl Zeiss, Thornwood, NY) equipped with appropriate filters and 
Axiovision Rel 4.5 image capture software. Images of fluorescently stained cells viewed through a 
10X objective were captured from three random fields in each treatment well. The percentage of 
FAM-stained cells per field was calculated by counting the total number of FAM-positive cells in each 
field and dividing by the total number of DAPI-stained nuclei in the same field. All caspase 
experiments were repeated three times. 
2.5. Human Melanoma Xenograft Studies 
New York Medical College institutional policy conforms to the U.S. Public Health Service Policy 
on Humane Care and Use of Laboratory Animals and all animal protocols were reviewed and 
approved by the institutional use and care of animals committee before experiments were begun. One 
million Line IV Cl 1 melanoma cells were inoculated intradermally into the flanks of either NCR 
athymic mice or Balb/c nu/nu mice obtained from the NIH production facility (Frederick, MD). 
SLT-VEGF treatment was started when tumors became palpable, which occurred at one and four 
weeks after tumor cell implantation in NCR athymic and Balb/c nu/nu hosts, respectively. Details of 
the treatment regimens are given in the Results section. The length, width, and height in mm of each 
tumor was measured weekly up to and including the date of tumor excision. Tumor volumes were 
estimated by calculating the average radius r  from length, width and height measurements and 
substituting into the formula, V = 2/3πr
3, for the volume of a hemisphere. Tumor growth rates were 
expressed as the slopes of linear regression curves calculated from the square roots of tumor volumes 
plotted against time. Transformation of tumor volumes in this manner yielded regression curves with 
straight line relationships whose slopes, therefore, provide robust estimates of tumor growth rates. In 
each study skin tumors were completely excised between six and seven weeks after they first became 
palpable and following a two week recovery period mice received five additional doses of SLT-VEGF 
on schedules detailed in the Results. The mice were followed until they showed signs of morbidity or 
until the conclusion of the study at 22 weeks post tumor cell inoculation. 
2.6. Lung Histology 
At sacrifice, lungs from mice in each study were perfused with formalin before being removed from 
the thoracic cavity. They were fixed overnight in 10% buffered formalin before being transferred to 
75% ethanol for storage. Paired left and right lungs from each mouse were processed for histological 
staining at either Albert Einstein College (Bronx, NY) or AML laboratories (Frederick, MD) where 
they were embedded in paraffin blocks and 3 micron-thick sections were cut and stained with 
hematoxylin and eosin. Slides were analyzed under a light microscope equipped with an ocular Toxins 2010, 2  
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gradicule (Olympus America, Inc, Medville, NY). The smallest diameter of each metastatic focus was 
measured with the five by five grid of the gradicule in which the sides of the individual small squares 
represent a distance of 0.261 mm at the 40× magnification used to view the slides. The number and 
diameters of all tumor foci in left and right lung sections of each animal were recorded and analyzed 
for statistical differences between treatment and control groups. 
2.7. Immunofluorescence Microscopy 
Harvested tumors were frozen in Optimal Tissue Cutting (OCT) compound and then cut on a 
cryotome into 7 µm sections and mounted on Plus slides (Fisher Scientific, Fair Lawn, NJ) for staining 
and analysis. We employed a previously published procedure for dual fluorescent immunostaining of 
VEGFR2 and CD31 [17]. Briefly, sections were blocked in normal rabbit serum and incubated with a 
primary rat, anti-mouse CD31 antibody (BD Biosciences San Jose, CA), then with a biotinylated rabbit 
anti-rat secondary antibody (Vector Labs, Burlingame, CA). CD31 staining was visualized by 
tyramide amplification with Alexa Fluor-594 TSA kits (Molecular Probes Carlsbad, CA) according to 
the manufacturer’s instructions. Excessive horseradish peroxidase activity was quenched by incubation 
with 5% H2O2 for 1 hour at RT, followed by incubation with rat, anti-mouse Flk-1(VEGFR-2) 
antibody (BD Biosciences). After washing and incubation with biotinylated rabbit anti-rat secondary 
antibody, VEGFR-2 staining was developed by tyramide amplification with Alexa Fluor-488 TSA kits 
(Molecular Probes). Cell nuclei were stained with VectorShield Mounting Medium containing DAPI 
(Vector Labs). VEGFR-2 and CD31 staining in tissues was quantitated by Photoshop (Adobe 
Photoshop version 5.0, Adobe Systems Incorporated, San Jose CA) analysis of images captured with 
an Axiovert 200 epifluourescent microscope and/or by high resolution scanning analysis with a Laser 
Scanning Cytometer (CompuCyte Corp. Cambridge, MA). In the first method, images were captured 
from at least five different 40× fields containing areas of high vascular density in each tumor section. 
The separate images of CD31 and VEGFR-2 staining were converted to tiff files and imported into 
Photoshop, where they were converted to gray scale and inverted so that positive staining appeared 
dark on a white background. The threshold function was adjusted to give binary black and white 
images that reflected the original staining pattern. The threshold setting was held constant for all 
images captured from all tumors and each image was analyzed with the histogram function to 
determine the percentage of the image area that contained black pixels as a readout for the amount of 
positive staining. In the second method, slides were scanned with a Laser Scanning Cytometer, whose 
red and green fluorescent photodetector channels were set at the same level for all tissue sections. 
Three areas with relatively homogeneous staining were chosen from low resolution scans of tumors to 
analyze at high resolution. Gates were set to exclude background staining in the red and green 
channels and the percentage of red only pixels, green only pixels, and red plus green pixels within each 
high resolution field were quantitated. These parameters provided readouts of total CD31 and VEGR-2 
staining within a selected area and precise quantitation of the percentage of co-localized staining. 
2.8. Statistics 
All statistical analyses were performed with Number Cruncher Statistical Software (NCSS) version 
2007 which includes routines to test datasets for the validity of assumptions of normal distribution and Toxins 2010, 2  
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equal variance. Data that met these assumptions were analyzed by ANOVA and post-hoc comparisons 
were performed with Dunnett’s one-sided multiple comparison test. The p-values of individual 
pairwise comparisons were calculated from the F-distribution. Statistical comparisons of data that 
were not normally distributed were made by the distribution-free Kruskal-Wallis multiple comparison 
Z-value test. The slopes of linear regression curves calculated from the square roots of tumor volumes 
plotted against time served as estimates of tumor growth rates and were compared for differences by 
two sample t-tests. Kaplan-Meier survival curves were constructed and the logrank test was applied to 
test for differences in survival between groups. Comparisons between two proportions were made with 
Fisher’s or with Barnard’s one-sided exact test for which p < 0.05 were considered significant. 
Quantitative data are presented graphically as box plots, in which rectangles represent the middle 50% 
of the data points, the median is shown as a line in the rectangle, and whiskers represent the high and 
low observations within the dataset. 
3. Results 
3.1. SLT-VEGF Activates Caspases 3/7 and 8 in Endothelial Cells Overexpressing VEGFR-2 but Not 
in Line IV Cl 1 Melanoma Cells  
We reported previously that SLT-VEGF is highly cytotoxic (IC50—0.2 nM) to PAE/KDR 
endothelial cells expressing ~2 × 10
5 VEGFR-2/cells, and that its cytotoxicity was ~20-fold lower for 
PAE cells lacking VEGFR-2 [18]. Considering that tumor cells may express VEGF receptors [19–21], 
and that even non-receptor mediated SLT-VEGF toxicity might be cell-specific, we explored the 
sensitivity of Line IV Cl 1 melanoma cells to SLT-VEGF in vitro. We found that these cells are 
essentially negative for VEGFR-2 expression (Figure 1A) and their growth is inhibited by SLT-VEGF 
at a 100-fold higher IC50 of 70 nM (Figure 1B). 
Figure 1. SLT-VEGF selectively targets VEGFR-2 expressing cells. High levels of 
VEGR-2 were detected on PAE/KDR cells (pink lines, A) by FACS analysis with a 
PE-labeled monoclonal antibody specifically recognizing human VEGFR-2 (R  &  D 
Systems, Minneapolis, MN). Untransfected PAE cells (green lines) and human Line IV Cl 1 
melanoma cells (blue lines) had negligible VEGFR-2 expression. When tested in a 
four day growth inhibition assay for sensitivity to SLT-VEGF, PAE/KDR cells had an IC50 
that was roughly 70–100 times lower than those of PAE cells and Line IV Cl 1 cells (B). 
 Toxins 2010, 2  
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In agreement with growth inhibition data, SLT-VEGF activated caspases 8 and 3/7 in PAE/KDR 
cells but not in Line IV Cl 1 melanoma cells, as measured by fluorescence microscopy with FLICA 8 
and FLICA 3/7 activated caspase detection reagents (Figure 2). As expected, activation of the apical 
caspase 8 was detected earlier in SLT-VEGF treated PAE/KDR cells than activation of effector 
caspases 3/7. Caspase 8 was activated at the 18 and 22 hour time points while caspase 3/7 activation 
was delayed until the 22 hour timepoint (all comparisons made by the Kruskal-Wallis multiple 
comparison test, α = 0.05). 
Figure 2. Caspase 8 and caspases 3/7 are activated by SLT-VEGF treatment of PAE/KDR 
cells. PAE/KDR cells treated with 26 nM SLT-VEGF had significant activation of caspase 8 
(A) as measured by the percentage of caspase positive cells in the FLICA assay at 18 and 
22 hours of incubation compared to untreated control cells. Caspase 3/7 (B) shows 
significant activation at 22 hours compared to control cells. 
 
3.2. SLT-VEGF Depletes Tumor Vasculature of VEGFR-2 Expressing Cells, but Does Not Inhibit 
Primary Tumor Growth 
Line IV Cl 1 melanoma cells developed palpable tumors in NCR athymic mice one week after 
intradermal inoculation of 1 × 10
6 cells into the flank. At that time mice were divided into treatment 
and control groups, which received twice weekly subcutaneous injections in 100 μL of injection saline 
of a total of five, 0.2 mg/kg doses of SLT-VEGF or saline vehicle alone prior to tumor excision. 
Immunofluorescent analysis of primary tumors revealed that most VEGFR-2 immunostaining 
colocalized with that of the pan-endothelial CD31 marker, but only a fraction of CD31
+ endothelial 
cells expressed detectable amounts of VEGFR-2 (Figure 3A). SLT-VEGF treatment resulted in 
selective depletion of VEGFR-2 expressing
 CD31
+ tumor endothelial cells (Figure 3A). Notably, those 
cells were particularly sensitive to SLT-VEGF treatment, leading to a 64% decrease in the ratio of 
VEGFR-2
+ to CD31
+ staining (Figure 3B) while there was not a significant decrease in total CD31 
staining (Figure 3C). Toxins 2010, 2  
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Figure 3. SLT-VEGF treatment results in selective depletion of VEGFR-2 expressing 
CD31
+ tumor endothelial cells. (A) Immunofluorescent staining of frozen melanoma tumor 
sections with Alexa-488 labeled anti-VEGFR-2 antibodies (green) and Alexa-594 labeled 
anti-CD31 antibodies (red) revealed that most VEGFR-2 is coexpressed with CD31 
positive endothelial cells. (B) VEGFR-2 and CD31 expression in melanoma tumors was 
quantitated by image analysis in Photoshop of six different 40× fields with high vascular 
density selected from each tumor. Dividing the percentage of image area positively stained 
with VEGFR-2 by that stained with CD31 yielded the VEGFR-2/CD31 ratio which was 
significantly (*: p = 0.013) reduced in SLT-VEGF treated tumors. (C) However, the total 
amount of CD31 staining in melanoma tumors was not significantly (p = 0.792) altered by 
SLT-VEGF treatment. 
 
Despite significant depletion of VEGFR-2
+/CD31
+ tumor endothelial cells, SLT-VEGF treatment 
did not affect the growth of primary tumors (Figure 4), suggesting that in our model such cells do not 
play a critical role in maintaining angiogenesis once tumors have achieved a certain growth threshold. 
In part, it might be due to their low prevalence in tumor vasculature, as judged by the low uptake of 
VEGFR-2 mediated scVEGF/Cy fluorescent tracer in this tumor relative to others, such as those 
elicited with human U87 MG glioma and MDA-MB-231 breast carcinoma cell lines (data not shown). Toxins 2010, 2  
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Figure 4. SLT-VEGF treatment does not significantly change the growth rate of orthotopic 
human melanoma tumors in NCR athymic mice. The growth rate of Line IV Cl 1 human 
melanoma tumors in control (n = 15, A) and SLT-VEGF (n = 20, B) treatment groups was 
estimated by linear regression on the square roots of tumor volumes against time. The 
average slopes ± 95% confidence intervals for tumor growth in control (3.52 ± 0.73) and 
SLT-VEGF treated (3.48 ± 0.58) mice were not significantly different. Both regression 
curves intersect the X-axis at or near the origin indicating that tumor cells inoculated in the 
skin of NCR athymic mice grow continuously from the time they are injected without a 
discernable lag period. 
 
3.3. SLT-VEGF Treatment Decreases the Incidence of Lung Metastases and Tumor Recurrence, and 
Improves the Overall Survival after Removal of Primary Tumor  
We reasoned that VEGFR-2
+/CD31
+ endothelial cells might play a more important role at the very 
early stages of tumor growth, when such cells appear in response to activation of a pro-angiogenic 
program in tumor cells, the so-called angiogenic switch [2]. We therefore explored effects of 
SLT-VEGF treatment on metastatic dissemination and tumor recurrence, according to the following 
experimental protocol. Primary tumors were excised between six and seven weeks after tumor 
inoculation and then, after two weeks of recovery, mice received five additional injections of 
0.2 mg/kg doses of SLT-VEGF or saline on a twice weekly schedule. We found that both the incidence 
(2/17  versus 5/11, p  = 0.038 by Barnard’s one-sided exact test) and the average number of 
histologically confirmed lung metastases per mouse were significantly lower (p < 0.05 by the 
Kruskal-Wallis  Z-value test, Figure 5A) in the SLT-VEGF group than in the control group. 
Interestingly, in the two SLT-VEGF treated mice that developed lung metastases the average diameter 
of tumor foci was larger (0.47 mm) than that of control mice (0.21 mm, p < 0.05). However the 
metastasis burden, here defined as the sum of the diameters of all foci in each set of lungs from mice 
with microscopic metastases, was not significantly different between SLT-VEGF treated and control 
animals (1.32 mm vs. 1.46 mm, p > 0.05). These results indicate that SLT-VEGF is effective in 
limiting the outgrowth of micrometastases and suggest that in instances where metastases do start 
growing they become insensitive to SLT-VEGF. In addition to its ability to reduce lung metastases, Toxins 2010, 2  
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SLT-VEGF treatment also inhibited post-surgical tumor recurrence (0/15 in SLT-VEGF treated vs. 
4/10 in control mice, p = 0.007) and improved survival (p = 0.002, Figure 5B). 
Figure 5. SLT-VEGF inhibits development of lung metastases and improves survival in 
NCR athymic mice following excision of Line IV Cl 1 human melanoma tumors.   
SLT-VEGF treated mice had a lower incidence of lung metastasis (p = 0.038, A) and 
survived significantly longer (p = 0.007, B) than control mice. 
 
3.4. SLT-VEGF Depletes Tumor Vasculature of VEGFR-2 Positive Cells, but Does Not Affect Tumor 
Growth, Metastatic Dissemination, Tumor Recurrence, and Overall Survival in a Mouse Host Whose 
Line IV Cl 1 Melanoma Tumors Have a Longer Dormancy Period 
To assess additional factors affecting responsiveness to SLT-VEGF treatment we used orthotopic 
Line IV Cl 1 tumors grown in Balb/c nu/nu mice. In this mouse strain, tumors developed over a longer 
dormancy period, becoming palpable at four weeks after intradermal injection of 1 × 10
6 cells/mouse, 
as opposed to one week for NCR athymic mice. Tumor-bearing Balb/c nu/nu mice were divided into 
saline control groups and treatment groups receiving SLT-VEGF at two different dose levels. 
Beginning at four weeks after tumor cell inoculation, mice in the latter two groups received a total of 
seven weekly injections of 0.1 mg/kg or 0.2 mg/kg doses of SLT-VEGF before surgical removal of 
primary tumors. After tumor excision, mice received an additional five 0.1 mg/kg or 0.2 mg/kg dose 
injections on a weekly schedule. At 0.2 mg/kg doses, VEGFR-2
+/CD31
+ endothelial cells were 
depleted from tumor vasculature (Figure 6A), total numbers of VEGFR-2
+  cells were reduced 
(Figure 6B) and total numbers of CD31
+ cells were not changed (Figure 6C); similar to our experience 
with NCR athymic mice. However, in this model, SLT-VEGF did not affect the growth of primary 
tumors, post-surgical local recurrence of tumors, incidence of metastatic dissemination, or overall 
survival (Figure 7A–C). Thus, in a model with a longer dormancy period, SLT-VEGF did not produce 
any measurable improvements, despite selective cytotoxicity to VEGFR-2
+/CD31
+ endothelial cells at 
the 0.2 mg/kg dose level. 
 Toxins 2010, 2  
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Figure 6. Reduction of VEGFR-2 expression on melanoma tumor vasculature by 
SLT-VEGF is dose dependent. Line IV Cl 1 tumors grown in Balb/c nu/nu mice were 
excised after treatment with 0.1 mg/kg or 0.2 mg/kg doses of SLT-VEGF then frozen, 
sectioned and immunostained for their content of VEGFR-2 and CD31 expressing cells. In 
these experiments high resolution laser scanning cytometry was applied to precisely 
quantitate the percentages of cells co-expressing these markers. The percentage of 
VEGFR-2
+/CD31
+ events (A) and total VEGFR-2
+ events (C) were significantly lower in 
the 0.2 mg/kg SLT-VEGF treatment group than in the 0.1 mg/kg treatment group and PBS 
control group, while total CD31
+ events (B) were unchanged. 
 Toxins 2010, 2  
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Figure 7. Tumor growth rate, incidence of lung metastases, and survival are not affected 
by SLT-VEGF treatment in a long tumor dormancy model of melanoma. Line IV Cl 1 cells 
did not develop measurable tumors until four weeks after inoculation into Balb/c nu/nu 
mice and displayed a two week dormancy period as indicated by the intersection with the 
X-axis of the regression curves calculated from the square roots of tumor volumes plotted 
against time (A and B). Growth rates of tumors as measured by slopes of the regression 
curves were not significantly different for SLT-VEGF treated (3.55 ± 0.34, B) and PBS 
control (3.37 ±  0.41,  A) groups. The incidence of lung metastases in the 2.5 and 
5 μg/injection dose groups of SLT-VEGF treated mice were not significantly different 
from the PBS control group (C). Although survival appears to be improved in mice in the 
5 μg SLT-VEGF injection dose group the difference between it and the PBS control group 
did not reach statistical significance by the logrank test (p = 0.198, D). 
 
4. Discussion 
We report here that SLT-VEGF, a fusion toxin that enters the cell via VEGF receptor mediated 
endocytosis, depletes VEGFR-2
+/CD31
+ endothelial cells from the vasculature of orthotopic Line IV 
Cl 1 melanoma tumors established in nude mice. This finding extends previously reported similar Toxins 2010, 2  
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effects of SLT-VEGF on the tumor vasculature of subcutaneous PC3 and 4T1 tumors [11]. However, 
unlike those models, the growth of orthotopically inoculated Line IV Cl 1 melanoma cells is not 
affected by SLT-VEGF, indicating that either the level of depletion of VEGFR-2
+/CD31
+ cells was not 
sufficient to inhibit tumor progression or that the contribution of VEGFR-2
+/CD31
+ endothelial cells to 
tumor progression is not critical in this model. 
We found that one million Line IV Cl 1 human melanoma cells inoculated intradermally into the 
flanks of NCR athymic mice formed palpable tumors 1 week after cell inoculation, whereas the same 
method and the same amount of cells inoculated in Balb/c nu/nu mice reproducibly did not produce 
similarly sized tumors until four weeks after inoculation. Even though the mechanism for such a 
difference remains unclear, we reasoned that we could use these two models, referred to here as short 
and long dormancy models, respectively, to study the effects of SLT-VEGF. 
In clinical practice melanoma skin lesions are surgically removed, but patients are at risk of disease 
progression due to metastatic dissemination of tumor cells that are undetectable at the time of surgery. 
We therefore explored the effects of SLT-VEGF on development of metastasis in a model system 
where orthotopic melanoma tumors established in the skin have a high propensity to metastasize to the 
lungs [15]. We found that SLT-VEGF inhibits the incidences of lung metastases and tumor recurrence 
after removal of primary Line IV Cl 1 melanoma in NCR athymic mice (short dormancy model). 
These data are in agreement with the results obtained in an orthotopic model of pancreatic cancer, in 
which SLT-VEGF inhibited metastatic dissemination [13]. In contrast, we found no statistically 
significant difference in the incidence of lung metastases among the treatment groups in a long 
dormancy melanoma model. 
These data indicate that even at this very early stage of tumor angiogenesis the contribution of 
VEGFR-2
+/CD31
+ endothelial cells might depend on the complex dynamics of tumor-host interactions. 
Indeed, as we have recently reported, SLT-VEGF treatment of a syngeneic murine 4T1 tumor started 
as early as four days after implantation of 2,000 cells/mouse resulted in a distinct separation of treated 
mice into “responders” and “non-responders”. Furthermore, an increase in SLT-VEGF dose changed 
the proportion of responders but not the degree of growth tumor inhibition [11]. 
We report here that SLT-VEGF works through initiation of caspase-dependent apoptosis in 
VEGFR-2 expressing cells. SLT holotoxin activates specifically caspases 8, 9, 3 and 6 [22,23]. We 
observed a significant level of caspase 3/7 and 8 activation in PAE/KDR cells, while no caspase 
activation was detected in the melanoma cells which express little or no VEGFR-2. These data, 
together with our previous work on activation of casapse 6 in PAE/KDR exposed to SLT-VEGF [18] 
indicate that, at least in vitro, SLT-VEGF activates caspases in the same manner as the holotoxin. 
It should be noted that two other targeted toxins containing VEGF have been reported to date, 
diphtheria toxin (DT) and gelonin [24–27]. Although they provided a “proof-of-principle” that 
VEGF-toxin fusion proteins work in vivo, their further development is doubtful for several reasons. 
First, the reported cytotoxicity of VEGF-DT to endothelial cells of normal vasculature (HUVEC) 
indicates that it would display high non-specific toxicity. In contrast, as we reported earlier and 
confirmed here, SLT-VEGF requires high levels of VEGFR-2 to exert cytotoxic effects [11,16,18]. 
Second, high immunogenicity and pre-existing immunity to DT is a serious obstacle for clinical 
development of VEGF-DT [28,29]. In contrast, SLT-VEGF induces only a low level anti-SLT serum 
response even after 3–5 consecutive injections [11]. Third, the low yield of VEGF-gelonin produced in Toxins 2010, 2  
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E. coli (0.23 mg/L) is problematic for its pre-clinical development [27]. As recently reported, we have 
developed a scalable GMP-compatible procedure for production of SLT-VEGF at a level of   
4–5 mg/L [11], which is a reasonable start for clinical development of SLT-VEGF. 
In conclusion, our data show that SLT-VEGF is a selectively cytotoxic anti-angiogenic protein that 
improves survival and inhibits metastasis in a short dormancy model of orthotopic melanoma. The 
narrow “window of vulnerability” for treatment with SLT-VEGF raises the questions about the 
translational potential of this targeted toxin. However, recent research on mechanisms of action of 
anti-angiogenic drugs that target VEGF/VEGFR signaling suggests a new opportunity for SLT-VEGF. 
Studies with several approved angiogenesis inhibitors indicate that they induce rapid vascular 
regression followed by revascularization, particularly at the edges of the tumor [30,31]. Since such 
revascularization supports continued tumor growth and metastatic dissemination, it is most likely 
responsible for the relatively low success rate of anti-angiogenic therapy. Our recent imaging studies 
in several tumor models indicate that revascularization is associated with a resurgence in the 
prevalence of VEGFR2
+/CD31
+ positive cells [30,31]. Preliminary results indicate that such 
revascularization could be inhibited by SLT-VEGF [11]. Experiments are now in progress to establish 
if combining angiogenesis inhibitors with SLT-VEGF might provide therapeutic benefits. 
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